Drug intelligence / Profile preview

PF-08046031

Development stage: Phase 1
Lead developer: Pfizer
Administration: Intravenous

Overview

PF-08046031 is an investigational drug developed by Pfizer, currently in Phase 1 clinical trials for the treatment of melanoma and other solid tumors that lack approved treatment options. The specific mechanism of action for PF-08046031 has not been disclosed publicly. The drug is administered intravenously and is being evaluated primarily for safety in patients with advanced or metastatic melanoma as well as other solid tumors.

Beyond the preview

Go deeper on PF-08046031.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PF-08046031.

Explore the full profile